{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:42:21Z","timestamp":1760071341087,"version":"build-2065373602"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>This article describes two pediatric SM with AML1::ETO+ AML patients induced by novel KIT exon11 mutations not previously documented in medical literature. Both patients underwent allogeneic hematopoietic stem cell transplantation, but subsequently developed refractory disease progression unresponsive to multiple salvage regiments. Strikingly, avapritinib intervention achieved unprecedented clinical responses in these complex cases.<\/jats:p>","DOI":"10.3389\/fped.2025.1646001","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:15:40Z","timestamp":1760069740000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Refractory systemic nmastocytosis with AML1::ETO+ acute myeloid leukemia driven by rare KIT mutation: remarkable therapeutic efficacy of avapritinib"],"prefix":"10.3389","volume":"13","author":[{"given":"Song","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjh.16288","article-title":"The clinical and pathological panoply of systemic mastocytosis","volume":"188","author":"Radia","year":"2020","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yexmp.2019.04.009","article-title":"Acute myeloid leukemia with t(8;21)(q22;q22.1)\/RUNX1-RUNX1T1 and KIT exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes","volume":"108","author":"Xie","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12308-009-0023-2","article-title":"Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia","volume":"2","author":"Pullarkat","year":"2009","journal-title":"J Hematop"},{"key":"B6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1182\/bloodadvances.2023012006","article-title":"A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/10428194.2024.2337795","article-title":"Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient","volume":"65","author":"Lin","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1309\/AJCP1Q0YSXEAHNKK","article-title":"Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)","volume":"140","author":"Johnson","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3109\/10428194.2011.647314","article-title":"Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia","volume":"53","author":"Kristensen","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41375-024-02182-1","article-title":"Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations on behalf of the EBMT practice harmonisation and guidelines committee","volume":"38","author":"McLornan","year":"2024","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41375-024-02186-x","article-title":"Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries","volume":"38","author":"Lubke","year":"2024","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11899-021-00650-4","article-title":"Avapritinib in the treatment of systemic mastocytosis: an update","volume":"16","author":"Below","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/10428194.2022.2064994","article-title":"Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKIT mutation relapse post allo-HSCT","volume":"63","author":"Xue","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4360304","DOI":"10.1155\/crh\/4360304","article-title":"KIT V560D-mutated systemic mastocytosis associated with high-risk myelodysplastic syndrome: a unique case of systemic mastocytosis-associated hematologic neoplasm","volume":"2024","author":"Medawar","year":"2024","journal-title":"Case Rep Hematol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1646001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T04:15:42Z","timestamp":1760069742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1646001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":18,"alternative-id":["10.3389\/fped.2025.1646001"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1646001","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1646001"}}